Case Report: BCMA-targeting CAR T-cell therapy induces complete and durable remission in relapsed extramedullary plasmablastic multiple myeloma

• Published in: Frontiers in immunology Vol. 16; p. 1567403
• Main Authors: Zhou, Lili, Cheng, Paul Ning Man, Mi, Jian-qing
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 2025
• Subjects: Antineoplastic Combined Chemotherapy Protocols - therapeutic use; B-Cell Maturation Antigen - immunology; BCMA CAR-T; Equecabtagene Autoleucel; extramedullary; Female; Humans; Immunotherapy, Adoptive - adverse effects; Immunotherapy, Adoptive - methods; maintenance; Middle Aged; Multiple Myeloma - immunology; Multiple Myeloma - therapy; plasmablastic multiple myeloma; Receptors, Chimeric Antigen - immunology; Remission Induction; Treatment Outcome; BCMA CAR-T; plasmablastic multiple myeloma; extramedullary; maintenance; Equecabtagene Autoleucel
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2025.1567403

Plasmablastic multiple myeloma (PBM) is an aggressive multiple myeloma (MM) form, identified by a high risk of recurrence and poor prognosis, with limited effective treatment options. Present study reports a case initially diagnosed with IgG-kappa MM with double-hit genetics. Following induction che...